Bridgeway Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-240,215
| Closed | -$889K | – | 1477 |
|
|
2017
Q4 | $889K | Hold |
240,215
| – | – | 0.01% | 884 |
|
|
2017
Q3 | $982K | Sell |
240,215
-25,000
| -9% | -$95.6K | 0.01% | 849 |
|
|
2017
Q2 | $985K | Buy |
265,215
+127,135
| +92% | +$504K | 0.01% | 830 |
|
|
2017
Q1 | $572K | Buy |
138,080
+120,565
| +688% | +$507K | 0.01% | 1028 |
|
|
2016
Q4 | $75K | Sell |
17,515
-2
| -0% | -$13 | ﹤0.01% | 1368 |
|
|
2016
Q3 | $172K | Buy |
17,517
+1,534
| +10% | +$10.9K | ﹤0.01% | 1343 |
|
|
2016
Q2 | $90K | Hold |
15,983
| – | – | ﹤0.01% | 1386 |
|
|
2016
Q1 | $122K | Sell |
15,983
-56,115
| -78% | -$432K | ﹤0.01% | 1356 |
|
|
2015
Q4 | $960K | Hold |
72,098
| – | – | 0.02% | 774 |
|
|
2015
Q3 | $1.19M | Sell |
72,098
-14,000
| -16% | -$287K | 0.02% | 674 |
|
|
2015
Q2 | $1.93M | Hold |
86,098
| – | – | 0.04% | 532 |
|
|
2015
Q1 | $842K | Hold |
86,098
| – | – | 0.02% | 867 |
|
|
2014
Q4 | $982K | Buy |
86,098
+47,333
| +122% | +$514K | 0.02% | 775 |
|
|
2014
Q3 | $447K | Buy |
38,765
+767
| +2% | +$11.7K | 0.01% | 1131 |
|
|
2014
Q2 | $739K | Hold |
37,998
| – | – | 0.02% | 909 |
|
|
2014
Q1 | $682K | Hold |
37,998
| – | – | 0.02% | 938 |
|
|
2013
Q4 | $401K | Hold |
37,998
| – | – | 0.01% | 1134 |
|
|
2013
Q3 | $470K | Hold |
37,998
| – | – | 0.02% | 1071 |
|
|
2013
Q2 | $358K | Buy |
+37,998
| New | +$488K | 0.01% | 1088 |
|
Bridgeway Capital Management's CASC Position: Q1 2018 in Review
Bridgeway Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 240,215 shares — an estimated $889K sold.
Bridgeway Capital Management first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $1.93M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Bridgeway Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Bridgeway Capital Management sold 240,215 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $889K.
- Bridgeway Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Bridgeway Capital Management's Cascadian Therapeutics, Inc. position peaked at $1.93M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Bridgeway Capital Management's 13F filing for Q1 2018, filed 15 May 2018.